ELV Stock Forecast & Price Target

Elevance Health's membership has increased approximately 10% year-over-year, with growth driven by expansion into new markets while maintaining strong retention in core Blue states. Management anticipates a minimum Medicare Advantage margin of 2% in 2026, reflecting a positive shift in pricing and membership mix, particularly towards D-SNPs, alongside continued strong performance in Commercial ASO and Medicaid. The company’s substantial scale, competitive local market share, and the strength of the BCBS brand position Elevance favorably for future growth, supported by an expected robust external pipeline for complex populations, indicating significant potential for margin expansion and earnings recovery across its business lines.

Elevance Health's outlook appears negative due to projected financial headwinds, including a deterioration of approximately 100 basis points in Medicaid margins and ongoing challenges within the commercial market, which reflects a higher risk environment for maintaining profitability. The company anticipates a significant decline in Medicaid membership by about 9% year-over-year, amounting to a reduction of roughly 750,000 members, attributed to stricter eligibility requirements and program changes. Furthermore, adjustments to earnings estimates have resulted in lowered EPS projections for 2026, reflecting a cautious view on future growth and potential adverse impacts from medical cost control and other operational challenges.